DeepMed Research

GC CELL CORPORATION

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies

Phase 1

Recruiting

Conditions: Lymphoma, T-Cell

Interventions: Drug: GCC2005
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2024-11-21

Last Posted Date: 2025-04-30

Lead Sponsor: GC Cell Corporation

Target Recruit Count: 48

Registration Number: NCT06699771

Locations: 🇰🇷
Seoul National University Hosptial, Seoul, Korea, Republic of
🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

and more 3 locations

Retrospective Study of Long-Term Survival of "Immuncell-LC" in Patients Undergoing Curative Resection for HCC in Korea

Not yet recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Biological: No Interventions
Biological: Immuncell-LC

First Posted Date: 2024-10-01

Last Posted Date: 2024-10-01

Lead Sponsor: GC Cell Corporation

Target Recruit Count: 230

Registration Number: NCT06620510

Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201

Phase 1

Withdrawn

Conditions: Breast Cancer
Gastroesophageal Junction Adenocarcinoma
Gastric Cancer

Interventions: Drug: AB-201
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2024-04-02

Last Posted Date: 2025-01-24

Lead Sponsor: GC Cell Corporation

Target Recruit Count: 48

Registration Number: NCT06341647

Locations: 🇦🇺
The Alfred Hosptial, Melbourne, Victoria, Australia
🇦🇺
Austin Hosptial, Melbourne, Victoria, Australia
🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With Psoriasis

Phase 1

Recruiting

Conditions: Moderate to Severe Plaque Psoriasis

Interventions: Genetic: CT303

First Posted Date: 2022-02-28

Last Posted Date: 2022-03-18

Lead Sponsor: GC Cell Corporation

Target Recruit Count: 24

Registration Number: NCT05258331

Locations: 🇰🇷
Pusan national university hospital, Pusan, Korea, Republic of
🇰🇷
Seoul national university hospital, Seoul, Korea, Republic of
🇰🇷
CHA Medical School Bundang CHA Medical Center, Gyeonggi-do, Korea, Republic of

Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With ARDS

Phase 1

Withdrawn

Conditions: Acute Respiratory Distress Syndrome

Interventions: Genetic: CT303

First Posted Date: 2022-02-14

Last Posted Date: 2023-04-04

Lead Sponsor: GC Cell Corporation

Registration Number: NCT05238532

Locations: 🇰🇷
Seoul national university boramae medical center, Seoul, Korea, Republic of
🇰🇷
Seoul National University Bundang Hospital, Seoul, Korea, Republic of
🇰🇷
Seoul national university hospital, Seoul, Korea, Republic of

Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer

Phase 3

Recruiting

Conditions: Pancreatic Ductal Adenocarcinoma

Interventions: Drug: Immuncell-LC
Drug: Gemcitabine

First Posted Date: 2021-07-21

Last Posted Date: 2021-11-22

Lead Sponsor: GC Cell Corporation

Target Recruit Count: 408

Registration Number: NCT04969731

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Daehak-ro, Jongno-gu, Korea, Republic of

Evaluate the Efficacy and Safety of 'Immuncell-LC' in Patients Undergoing Liver Transplantation

Phase 1

Completed

Conditions: Liver Transplantation

Interventions: Biological: Immuncell-LC

First Posted Date: 2019-06-12

Last Posted Date: 2023-06-22

Lead Sponsor: GC Cell Corporation

Target Recruit Count: 19

Registration Number: NCT03983967

Locations: 🇰🇷
Seoul National Hospital, Seoul, Korea, Republic of

MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin

Phase 1

Conditions: Relapsed Non Hodgkin Lymphoma
Refractory Non-Hodgkin Lymphoma

Interventions: Drug: Rituximab
Drug: Fludarabine
Drug: Cyclophosphamide
Biological: MG4101(allogeneic Natural Killer cell)
Drug: Interleukin-2

First Posted Date: 2018-12-19

Last Posted Date: 2020-07-28

Lead Sponsor: GC Cell Corporation

Target Recruit Count: 9

Registration Number: NCT03778619

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷
Seoul National Univ. Hospital, Seoul, Korea, Republic of

Safety and Efficacy of "Immuncell-LC" in TACE Therapy

Phase 2

Completed

Conditions: Carcinoma, Hepatocellular

Interventions: Biological: Immuncell-LC

First Posted Date: 2016-08-05

Last Posted Date: 2023-06-22

Lead Sponsor: GC Cell Corporation

Target Recruit Count: 76

Registration Number: NCT02856815

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Daehak-ro 101/Jongno-gu, Korea, Republic of
🇰🇷
Seoul St.Mary's Hospital, Seoul, Banpo-daero 222 / Seocho-go, Korea, Republic of
🇰🇷
Severance Hospital, Seoul, Seoul,50-1 Yonsei-ro/Seodaemun-gu, Korea, Republic of

A Study of MG4101 (Allogeneic Natural Killer Cell) for Intermediate-stage of Hepatocellular Carcinoma

Phase 2

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Biological: MG4101

First Posted Date: 2016-08-04

Last Posted Date: 2019-09-26

Lead Sponsor: GC Cell Corporation

Target Recruit Count: 78

Registration Number: NCT02854839

Locations: 🇰🇷
Ajou Univ. Hospital, Suwon, Korea, Republic of
🇰🇷
Severance hospital, Seoul, Korea, Republic of
🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy